BRCTF Quote, Financials, Valuation and Earnings

BioInvent International AB has a net margin of -4.8% compared to BioArctic AB's net margin of -4171.4%. BioArctic AB's return on equity of 52.54% beat BioInvent International AB's return on equity of -45.16%.

BioArctic AB has a consensus price target of --, signalling downside risk potential of --. On the other hand BioInvent International AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioArctic AB has higher upside potential than BioInvent International AB, analysts believe BioArctic AB is more attractive than BioInvent International AB.

BioArctic AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioInvent International AB has a beta of 0.850, suggesting its less volatile than the S&P 500 by 14.984%.

BioArctic AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioInvent International AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioArctic AB pays 17.32% of its earnings as a dividend. BioInvent International AB pays out -- of its earnings as a dividend. BioArctic AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioArctic AB quarterly revenues are $19.6M, which are larger than BioInvent International AB quarterly revenues of $320.6K. BioArctic AB's net income of -$938.5K is higher than BioInvent International AB's net income of -$13.4M. Notably, BioArctic AB's price-to-earnings ratio is 30.55x while BioInvent International AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioArctic AB is 14.99x versus 9.32x for BioInvent International AB. Usually stocks with elevated PS ratios are considered overvalued.

Camurus AB has a net margin of -4.8% compared to BioArctic AB's net margin of 21.72%. BioArctic AB's return on equity of 52.54% beat Camurus AB's return on equity of 19.19%.

BioArctic AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Camurus AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioArctic AB has higher upside potential than Camurus AB, analysts believe BioArctic AB is more attractive than Camurus AB.

BioArctic AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Camurus AB has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.17%.

BioArctic AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Camurus AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioArctic AB pays 17.32% of its earnings as a dividend. Camurus AB pays out -- of its earnings as a dividend. BioArctic AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioArctic AB quarterly revenues are $19.6M, which are smaller than Camurus AB quarterly revenues of $49.4M. BioArctic AB's net income of -$938.5K is lower than Camurus AB's net income of $10.7M. Notably, BioArctic AB's price-to-earnings ratio is 30.55x while Camurus AB's PE ratio is 44.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioArctic AB is 14.99x versus 14.30x for Camurus AB. Usually stocks with elevated PS ratios are considered overvalued.

Hansa Biopharma AB has a net margin of -4.8% compared to BioArctic AB's net margin of -217.19%. BioArctic AB's return on equity of 52.54% beat Hansa Biopharma AB's return on equity of --.

BioArctic AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Hansa Biopharma AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioArctic AB has higher upside potential than Hansa Biopharma AB, analysts believe BioArctic AB is more attractive than Hansa Biopharma AB.

BioArctic AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Hansa Biopharma AB has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.963%.

BioArctic AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hansa Biopharma AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioArctic AB pays 17.32% of its earnings as a dividend. Hansa Biopharma AB pays out -- of its earnings as a dividend. BioArctic AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioArctic AB quarterly revenues are $19.6M, which are larger than Hansa Biopharma AB quarterly revenues of $8.1M. BioArctic AB's net income of -$938.5K is higher than Hansa Biopharma AB's net income of -$17.5M. Notably, BioArctic AB's price-to-earnings ratio is 30.55x while Hansa Biopharma AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioArctic AB is 14.99x versus 10.42x for Hansa Biopharma AB. Usually stocks with elevated PS ratios are considered overvalued.

Orexo AB has a net margin of -4.8% compared to BioArctic AB's net margin of -3503.14%. BioArctic AB's return on equity of 52.54% beat Orexo AB's return on equity of -134.37%.

BioArctic AB has a consensus price target of --, signalling downside risk potential of --. On the other hand Orexo AB has an analysts' consensus of -- which suggests that it could fall by --. Given that BioArctic AB has higher upside potential than Orexo AB, analysts believe BioArctic AB is more attractive than Orexo AB.

BioArctic AB has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Orexo AB has a beta of 0.260, suggesting its less volatile than the S&P 500 by 73.999%.

BioArctic AB has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Orexo AB offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioArctic AB pays 17.32% of its earnings as a dividend. Orexo AB pays out -- of its earnings as a dividend. BioArctic AB's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioArctic AB quarterly revenues are $19.6M, which are larger than Orexo AB quarterly revenues of $350.8K. BioArctic AB's net income of -$938.5K is higher than Orexo AB's net income of -$12.3M. Notably, BioArctic AB's price-to-earnings ratio is 30.55x while Orexo AB's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioArctic AB is 14.99x versus 2.04x for Orexo AB. Usually stocks with elevated PS ratios are considered overvalued.